[RobinP]

Al thanks for your article submission; very interesting and encouraging for cancer treatment. I think as we know more about the molecular make-up of individual breast caner tumors, the better we can target therapy with various agents, not just with Herceptin alone, particularly in those who do not respond or have full or lasting response. I find it interesting that a lot of these target therapies work better together, ig Laptatinib and Herceptin. Avastin works better with Taxol we now know but perhaps even better Herceptin and Lapatinib and perhaps even with Maytasinoid. There's a lot of potential out there. However, I really think the targets must be defined better with more complex pathologies on tumors testing for such things as her1,2,3,4, bcl2, and various markers for kinase activity. Then rather than randomly treating patients with these therapies, we can specifically treat, save toxicities, not to mention money.